CD40, His, Human
| $220.00 | |
| Z03647-100 | |
|
|
|
|
|
|
|
|
|
| Ask us a question | |
IVD Raw Materials
| $220.00 | |
| Z03647-100 | |
|
|
|
|
|
|
|
|
|
| Ask us a question | |
| Species | Human | ||||
| Protein Construction |
|
||||
| Purity | > 95% as determined by Bis-Tris PAGE | ||||
| Endotoxin Level | ≤ 1 EU/μg of protein by LAL method | ||||
| Biological Activity | Measured by its binding ability in a functional ELISA.Test result was comparable to standard batch. | ||||
| Expression System | HEK293 | ||||
| Theoretical Molecular Weight | 20 kDa | ||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 35-40 kDa based on Bis-Tris PAGE result. | ||||
| Formulation | Lyophilized from a 0.22 μm filtered solution in PBS, pH 7.4. | ||||
| Reconstitution | It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH₂O more than 100 μg/ml. | ||||
| Storage & Stability | Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles. |
Immobilized Human CD40, His Tag at 0.5 μg/ml (100 μl/Well). Dose response curve for Human CD40L, hFc Tag with the EC50 of 0.22 μg/ml determined by ELISA. »
The purity of Human CD40 is greater than 95% as determined by SEC-HPLC. »
Immobilized CD40, His, Human, His Tag at 2 μg/ml (100 μl/well) on the plate. Dose response curve for Human CD40 Ligand (Trimer), hFc Tag with the EC50 of 77.0ng/ml determined by ELISA. »
CD40, His, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »
| Target Background | CD40 is a costimulatory protein found on antigen presenting cells and is required for their activation. The binding of CD154 (CD40L) on TH cells to CD40 activates antigen presenting cells and induces a variety of downstream effects.CD40 molecule is a potential target for cancer immunotherapy. There are number of completed and ongoing clinical trials where agonistic anti-CD40 monoclonal antibodies are employed to activate an anti-tumor T cell response via activation of dendritic cells. |
| Synonyms | CD40; CD40L receptor; TNFRSF5; B cell surface antigen CD40; B-cell surface antigen CD40; Bp50B cell-associated molecule; CD40 antigen; CD40 molecule, TNF receptor superfamily member 5; CD40 type II isoform; CDw40; MGC9013; nerve growth factor receptor-related B-lymphocyte activation molecule; p50; TNFRSF5CD40 antigen (TNF receptor superfamily member 5); tumor necrosis factor receptor superfamily member 5; tumor necrosis factor receptor superfamily, member 5 |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.